Since Vioxx's removal from the market, safety concerns on other
drugs in its class, known as COX-2 inhibitors, have been raised.
With an estimated 30,000 to 100,000 Vioxx users having adverse
side effects, including heart attacks and strokes, it's no wonder
researchers are concerned with the use of similar drugs in its class.
In regard to this estimate, the president of Merck chose not to
comment. However, a company spokesperson claimed the results were
inaccurate, saying it is impossible to base data from one study
to account for all Vioxx users.
One drug in particular under surveillance is Celebrex, made by
Pfizer. This drug, along with Vioxx, has been among the widest prescribed
medications in the United States.
Studies on the mechanics of COX-2 inhibitors have led researchers
to believe that drugs like Celebrex will have similar adverse side
effects and should be noted as "risky." In fact, some
signs of increased cardiovascular risks have already been detected
in clinical trials of COX-2 inhibitors.
On the other hand, the vice president of Pfizer explained that
clinical trials have indicated that Celebrex does not reflect the
same cardiovascular side effects as Vioxx. He further explained
that although the two drugs are in the same class, each is in a
subclass of its own with different chemical structures and safety
profiles.
Some researchers suggest it is time for the FDA to step up and
take control of the situation by adjusting its guidance to patients
and doctors based on this new information. They further claim the
FDA should have taken a more aggressive role in making sure Vioxx
and other COX-2 drugs were safe, considering the risks brought to
public's attention in 2000 on using Vioxx.
Washington
Post October 7, 2004
| 